期刊
MOLECULAR PHARMACEUTICS
卷 18, 期 5, 页码 2032-2038出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.1c00008
关键词
gene therapy; triple negative breast cancer; nanoparticles; angiogenesis
资金
- NCI Center Core Support Grant [5P30CA016086-41]
- [P30 CA016086]
The study found that Tinagl1 gene therapy can slow tumor growth in triple negative breast cancer without toxicity. Additionally, the use of Tinagl1 significantly increases tumor vasculature without increasing permeability or metastasis risk. Furthermore, the increase in vasculature from Tinagl1 therapy reduces the expression of Hif1a, potentially decreasing drug resistance risk.
Triple negative breast cancer (TNBC) remains one of the most challenging subtypes of breast cancer to treat and is responsible for approximately 12% of breast cancer cases in the US per year. In 2019, the protein Tinagl1 was identified as a key factor for improved prognoses in certain TNBC patients. While the intracellular mechanism of action has been thoroughly studied, little is known about the role of Tinagl1 in the tumor microenvironment. In this study, we developed a lipid nanoparticle-based gene therapy to directly target the expression of Tinagl1 in tumor cells for localized expression. Additionally, we sought to characterize the changes to the tumor microenvironment induced by Tinagl1 treatment, with the goal of informing future choices for combination therapies including Tinagl1. We found that Tinagl1 gene therapy was able to slow tumor growth from the first dose and that the effects held steady for nearly a week following the final dose. No toxicity was found with this treatment. Additionally, the use of Tinagl1 increases the tumor vasculature by 3-fold but does not increase the tumor permeability or risk of metastasis. However, the increase in vasculature arising from Tinagl1 therapy reduced the expression of Hif1a significantly (p < 0.01), which may decrease the risk of drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据